Celgene Revlimid Post-Market Phase III Study To Explore Lower Dose

Celgene's Phase III study for its myelodysplastic syndromes therapy Revlimid will examine lower doses, the company told FDA's Oncologic Drugs Advisory Committee on Sept. 14

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet